A Phase I/IIa, Open Label, Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1/LAGE-1 in Patients with Recurrent or Treatment Refractory Ovarian Cancer
Description: 

The primary study objective is to determine the safety and tolerability of this combination therapy regimen with autologous redirected T cell therapy in patients with treatment refractory or resistent Stage III/IV ovarian cancer.

Study Number: 

I 230612

Phase: 
I / II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01567891

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.